Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease.
about
The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementiaCLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/collagen type XXVThe presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residuealpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodiesNUB1 suppresses the formation of Lewy body-like inclusions by proteasomal degradation of synphilin-1Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body diseaseNext-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.Ribosylation rapidly induces alpha-synuclein to form highly cytotoxic molten globules of advanced glycation end products.alpha-Synuclein abnormalities in mouse models of peroxisome biogenesis disorders.Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.LRRK2 in Parkinson's disease and dementia with Lewy bodies.Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.Nonselenium glutathione peroxidase in human brain : elevated levels in Parkinson's disease and dementia with lewy bodiesSynchrotron FTIR micro-spectroscopy for structural analysis of Lewy bodies in the brain of Parkinson's disease patients.Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synucleinProteomic identification of novel proteins associated with Lewy bodies.Alpha-synuclein alters Notch-1 expression and neurogenesis in mouse embryonic stem cells and in the hippocampus of transgenic mice.Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy.Challenges in structural approaches to cell modeling.Generation, purification, and characterization of cell-invasive DISC1 protein species.Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy.SUMOylation and ubiquitination reciprocally regulate α-synuclein degradation and pathological aggregation.Unbiased Proteomics of Early Lewy Body Formation Model Implicates Active Microtubule Affinity-Regulating Kinases (MARKs) in Synucleinopathies.α-Synuclein interacts directly but reversibly with psychosine: implications for α-synucleinopathies
P2860
Q22252705-E64FAF11-4515-4996-A0F4-1559550F1FA4Q24292980-95B82214-31F5-4E80-B746-B72E1A99C48EQ24564792-84C5F7E4-DBEA-4312-BBEB-11BC4DDEE563Q24653247-DB2A90E0-F524-4973-9D13-70B78F9A1BEAQ24671360-766A924F-D3E3-43FC-921F-E247DA6A5E6CQ28740551-06F3AEDB-D53A-4E47-B8BD-30110B79E616Q30578913-8ACCF3F4-9100-4220-97AB-B97E9C5593EEQ33530116-5835DC19-CBE0-4B6F-9236-C637536E1967Q33643679-3971324D-7567-4A34-8B31-B1D185440995Q33703950-959EB005-5EB7-4D84-81B2-C6B7EF7D810BQ33865366-2F65353C-673F-4D45-AFBB-9BD0689709AEQ35214380-D1B4B7CA-5755-4D60-B89E-6921CA5E7E6BQ35764504-D26A9DDC-C16E-47A2-A2EE-BFCEA0F43D33Q35789018-99CA152D-5B12-45D6-82F3-1C6DE28831F7Q36333500-5BE01C3C-D1B9-48B9-A25C-B768F4CF26E0Q36658992-3C406934-4173-4F48-A47C-0B5F05D15766Q37146740-F18AC7A2-D69E-4078-B2A4-46420F69D3B1Q37152191-278AE88E-9D1A-4DEF-B3A0-62D38FA7416AQ37586721-49A84229-C40F-4647-AA9B-CABA86E4E30CQ38851972-52D290D0-8EAC-4EED-9AFD-B3A3EEB4236DQ39284833-08D996ED-7BD3-4BD2-8AEF-2D3873E73BB4Q46124320-6A288D08-F084-477B-B42C-439F391411D7Q47359062-DA53BB94-8F1B-46F0-8C92-D08CA535F1F0Q48124425-C8A7E9EB-577C-404C-8867-6576E6D53C5AQ58765487-27DC7944-52EB-4E67-91AF-B00B17DA70C4
P2860
Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Purification and characterizat ...... ith diffuse Lewy body disease.
@ast
Purification and characterizat ...... ith diffuse Lewy body disease.
@en
type
label
Purification and characterizat ...... ith diffuse Lewy body disease.
@ast
Purification and characterizat ...... ith diffuse Lewy body disease.
@en
prefLabel
Purification and characterizat ...... ith diffuse Lewy body disease.
@ast
Purification and characterizat ...... ith diffuse Lewy body disease.
@en
P2093
P2860
P1476
Purification and characterizat ...... ith diffuse Lewy body disease.
@en
P2093
Fujimuro M
Iwatsubo T
Trojanowski JQ
Yamaguchi H
Yokosawa H
P2860
P304
P407
P577
1996-05-01T00:00:00Z